All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new treatment combinations improve outcomes in TP53 mutant AML?
How could new treatment combinations improve outcomes in TP53 mutant AML?
Daver begins by discussing a recent study that analyzed patients on hypomethylating agents (HMA) versus cytarabine based regimens. He highlights that HMA based therapy maintained better response rates regardless of TP53 variant allele frequency, unlike the cytrabine regimen. He goes on to outline further HMA regimens, such as combinations with venetoclax. He then discusses immune therapies such as magrolimab and their outcomes. Finally, he explains the results of the recent study using APR-246 and the promising activity of natural killer (NK) and NK CAR-T cell based therapies.
Visual abstract | Azacitidine with venetoclax and magrolimab in patients with ND or R/R AML
We present a visual abstract representing key data from a phase I/II trial investigating the triplet combination of azacitidine, venetoclax, and magrolimab...
AML Hub Satellite Symposium: How does MRD impact outcome of stem cell transplantation in AML, now and in the future?
At the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub will hold a satellite...
Subscribe to get the best content related to AML delivered to your inbox